WO2021021877A1 - Gipr-agonist compounds - Google Patents
Gipr-agonist compounds Download PDFInfo
- Publication number
- WO2021021877A1 WO2021021877A1 PCT/US2020/043988 US2020043988W WO2021021877A1 WO 2021021877 A1 WO2021021877 A1 WO 2021021877A1 US 2020043988 W US2020043988 W US 2020043988W WO 2021021877 A1 WO2021021877 A1 WO 2021021877A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- acceptable salt
- ethoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 157
- 239000000556 agonist Substances 0.000 title description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 28
- 208000008589 Obesity Diseases 0.000 claims abstract description 24
- 235000020824 obesity Nutrition 0.000 claims abstract description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims description 86
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 41
- 102000004877 Insulin Human genes 0.000 claims description 39
- 108090001061 Insulin Proteins 0.000 claims description 39
- 229940125396 insulin Drugs 0.000 claims description 38
- 238000002560 therapeutic procedure Methods 0.000 claims description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 12
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 12
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 51
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract description 14
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract description 9
- 108020003175 receptors Proteins 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 5
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 22
- 150000001413 amino acids Chemical group 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- -1 a-methyl leucine Chemical class 0.000 description 13
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 12
- 102100040918 Pro-glucagon Human genes 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 230000009977 dual effect Effects 0.000 description 9
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 7
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 7
- 102000051325 Glucagon Human genes 0.000 description 7
- 108060003199 Glucagon Proteins 0.000 description 7
- 108010063919 Glucagon Receptors Proteins 0.000 description 7
- 102100040890 Glucagon receptor Human genes 0.000 description 7
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 7
- 102400000319 Oxyntomodulin Human genes 0.000 description 7
- 101800001388 Oxyntomodulin Proteins 0.000 description 7
- 229940100389 Sulfonylurea Drugs 0.000 description 7
- 229940123464 Thiazolidinedione Drugs 0.000 description 7
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 7
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 7
- 229960004666 glucagon Drugs 0.000 description 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 7
- 229960003105 metformin Drugs 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000002821 scintillation proximity assay Methods 0.000 description 7
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229940123232 Glucagon receptor agonist Drugs 0.000 description 6
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 6
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 6
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 6
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940044601 receptor agonist Drugs 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- ZEBBPGHOLWPSGI-KPLDDXDLSA-N urocortin ii Chemical class CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(N)=O)CC1=CN=CN1 ZEBBPGHOLWPSGI-KPLDDXDLSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 108010088847 Peptide YY Proteins 0.000 description 5
- 102100029909 Peptide YY Human genes 0.000 description 5
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 108010001478 Bacitracin Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 229960003071 bacitracin Drugs 0.000 description 4
- 229930184125 bacitracin Natural products 0.000 description 4
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 4
- 229960004015 calcitonin Drugs 0.000 description 4
- 239000011539 homogenization buffer Substances 0.000 description 4
- 239000000859 incretin Substances 0.000 description 4
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- YPTNAIDIXCOZAJ-LHEWISCISA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[(4-methylphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(C)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NCCCC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 YPTNAIDIXCOZAJ-LHEWISCISA-N 0.000 description 3
- 229940124035 Amylin receptor agonist Drugs 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 101100228914 Homo sapiens GIPR gene Proteins 0.000 description 3
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 3
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 2
- 108010001789 Calcitonin Receptors Proteins 0.000 description 2
- 102100038520 Calcitonin receptor Human genes 0.000 description 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 2
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 244000137850 Marrubium vulgare Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GCHPUFAZSONQIV-YFKPBYRVSA-N (2s)-2-azaniumyl-2-methylbutanoate Chemical compound CC[C@](C)([NH3+])C([O-])=O GCHPUFAZSONQIV-YFKPBYRVSA-N 0.000 description 1
- FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 1
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- MNBYXFWXRDWBOQ-UHFFFAOYSA-N 2-[2-[2-amino-3-(9H-fluoren-9-ylmethoxy)-3-oxopropoxy]ethoxy]acetic acid Chemical compound C(=O)(OCC1C2=CC=CC=C2C2=CC=CC=C12)C(COCCOCC(=O)O)N MNBYXFWXRDWBOQ-UHFFFAOYSA-N 0.000 description 1
- UPMGJEMWPQOACJ-UHFFFAOYSA-N 2-[4-[(2,4-dimethoxyphenyl)-(9h-fluoren-9-ylmethoxycarbonylamino)methyl]phenoxy]acetic acid Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(O)=O)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPMGJEMWPQOACJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ARSWQPLPYROOBG-ZETCQYMHSA-N 2-methylleucine Chemical compound CC(C)C[C@](C)(N)C(O)=O ARSWQPLPYROOBG-ZETCQYMHSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- KPFBUSLHFFWMAI-HYRPPVSQSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-formyl-3-methoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=C(C=O)C[C@H]2[C@@H]2CC[C@](OC(C)=O)(C(C)=O)[C@]21C KPFBUSLHFFWMAI-HYRPPVSQSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- JGPOSNWWINVNFV-UHFFFAOYSA-N carboxyfluorescein diacetate succinimidyl ester Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O JGPOSNWWINVNFV-UHFFFAOYSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 229940127208 glucose-lowering drug Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 102000056448 human GLP1R Human genes 0.000 description 1
- 102000050325 human granulocyte inhibitory Human genes 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Natural products OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor.
- GIP human glucose-dependent insulinotropic polypeptide
- the present invention also relates to compounds having an extended duration of action at the GIP receptor.
- Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
- T2DM is the most common form of diabetes, accounting for approximately 90% of all diabetes.
- T2DM is characterized by high blood glucose levels associated mainly with insulin resistance.
- the current standard of care for T2DM includes diet and exercise, treatment with oral medications, and injectable glucose-lowering drugs, including incretin-based therapies such as GLP-1 receptor agonists.
- GLP-1 receptor agonists are currently available for treatment of T2DM, although currently marketed GLP-1 receptor agonists are generally dose-limited by gastrointestinal side effects such as nausea and vomiting.
- Subcutaneous injection is the typical route of administration for the available GLP-1 receptor agonists.
- oral medications and incretin-based therapies are insufficient, insulin treatment is considered.
- T2DM is unable to reach their glycemic control goals.
- Uncontrolled diabetes leads to several conditions associated with increased morbidity and mortality of patients.
- Obesity is a complex medical disorder resulting in excessive accumulation of adipose tissue mass.
- Today obesity is a global public health concern that is associated with undesired health outcomes and morbidities. Desired treatments for patients with obesity should reduce excess body weight, improve obesity-related co-morbidities, and maintain long-term weight reduction. Available treatments for obesity are particularly unsatisfactory for patients with severe obesity. There is a need for alternative treatment options to induce therapeutic weight loss in patients in need of such treatment.
- WO2016/111971 describes peptides stated to have GLP-1R and GIPR agonist activities.
- WO2013/164483 also discloses compounds stated to have GLP-1R and GIPR activities.
- WO2018/181864 discloses compounds stated to have GIPR agonist activity.
- T2DM treatments capable of providing effective glucose control for a larger portion of the patients in need of such treatment.
- T2DM treatments capable of providing effective glucose control and with a favorable side effect profile.
- alternate treatment options to provide therapeutic weight loss in a patient in need of such treatment, such as a patient with severe obesity.
- diabetes treatment options may be combined with insulin therapy and/or incretin therapy to provide the patient with superior glycemic outcomes and/or more desirable side effect profiles.
- Compounds with extended duration of action at the GIP receptor are desirable to allow for less frequent dosing of the compound.
- embodiment 1 is a compound of Formula I
- Z 1 is a modification of the N-terminal amino group wherein the modification is selected from the group consisting of acetyl and absent;
- X 1 is selected from the group consisting of Y and D-Tyr;
- X 2 is selected from the group consisting of Aib, A, and D-Ala ;
- X 6 is selected from the group consisting of F, aMeF, Iva, L, aMeL, and aMeF(2F);
- X 13 is selected from the group consisting of aMeL, A, L, and Aib;
- X 16 is selected from the group consisting of K, E, and Orn;
- X 17 is selected from the group consisting of I and K(2-[2-(2-amino-ethoxy)- ethoxy]- acetyl) 2 -(g-Glu)-CO-(CH 2 )q-CO 2 H;
- X 18 is selected from the group consisting of H, A, and R;
- X 20 is selected from the group consisting of Aib and Q;
- X 21 is selected from the group consisting of D and E;
- X 22 is selected from the group consisting of F and aMeF;
- X 24 is selected from the group consisting of E, N, Q, and D-Glu
- X 25 is selected from the group consisting of Y, 4-Pal, W, and aMeY;
- X 26 is selected from the group consisting of L and K(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl) 2 -(g-Glu)-CO-(CH 2 )q-CO 2 H;
- X 28 is selected from the group consisting of E and A;
- X 29 is selected from the group consisting of G, A, Q, and T; q is selected from the group consisting of 16 and 18; and
- Z 2 is absent or a modification of the C-terminal group, wherein the modification is amidation;
- X 17 and X 26 is K(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl) 2 -(g-Glu)-CO-(CH 2 )q-CO 2 H;
- An embodiment 2 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 1 wherein Z 1 is absent and X 1 is Y.
- An embodiment 3 provides a compound, or pharmaceutically acceptable salt thereof, of embodiment 1 or embodiment 2 wherein X 2 is Aib.
- An embodiment 4 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 3 wherein:
- X 6 is selected from the group consisting of F and aMeF (2F).
- An embodiment 5 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 4 wherein:
- X 13 is selected from the group consisting of L and aMeL.
- An embodiment 6 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 5 wherein X 16 is K or Orn.
- An embodiment 7 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 6 wherein X 16 is K.
- An embodiment 8 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 7 wherein X 18 is H.
- An embodiment 9 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 8 wherein X 20 is Aib; and X 22 is F.
- An embodiment 10 provides a compound, or a pharmaceutically acceptable salt thereof, as claimed of any one of embodiments 1 to 9 wherein X 2 1 is D.
- An embodiment 11 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 10 wherein X 25 is 4-Pal or Y.
- An embodiment 12 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 11 wherein:
- X 17 is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) 2 -(g-Glu)-CO-(CH 2 )q-CO 2 H;
- X 26 is L.
- An embodiment 13 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 11 wherein:
- X 17 is I
- X 26 is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) 2 -(g-Glu)-CO-(CH 2 )q-CO 2 H.
- An embodiment 14 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 13 wherein q is 16.
- An embodiment 15 provides a compound, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 13 wherein q is 18.
- An embodiment 16 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 1 wherein: Z 1 is absent;
- X 1 is Y
- X 2 is selected from the group consisting of Aib and D-Ala; X 6 , is F;
- X 13 is selected from the group consisting of aMeL and L;
- X 16 is selected from the group consisting of K and Orn;
- X 18 is selected from the group consisting of H and A;
- X 20 is Aib
- X 22 is F
- X 24 is selected from the group consisting of E, N, and D-Glu;
- X 25 is selected from the group consisting of Y, 4-Pal, and W;
- X 28 is selected from the group consisting of E and A;
- X 29 is selected from the group consisting of G, A, and Q; and q is selected from the group consisting of 16 and 18.
- An embodiment 17 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 16 wherein:
- X 2 is Aib
- X 13 is aMeL
- X 18 is H
- X 24 is selected from the group consisting of E and D-Glu;
- X 25 is selected from the group consisting of Y and 4-Pal;
- X 28 is E
- X 29 is selected from the group consisting of G and A.
- An embodiment 18 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 17 wherein: X 17 is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) 2 -(g- Glu)-CO-(CH 2 ) q -CO 2 H; and
- X 26 is L.
- An embodiment 19 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 17 wherein: X 17 is I; and X 26 is K(2-[2-(2-amino-ethoxy)-ethoxy]- acetyl) 2 -(g-Glu)-CO-(CH 2 )q-CO 2 H.
- An embodiment 20 provides a compound, or a pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.
- An embodiment 21 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NQ:5.
- An embodiment 22 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NO:6.
- An embodiment 23 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NQ:7.
- An embodiment 24 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NO:8.
- An embodiment 25 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NO:9.
- An embodiment 26 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NO: 10.
- An embodiment 27 provides a compound or pharmaceutically acceptable salt thereof, of embodiment 1 wherein the compound is SEQ ID NO: 11.
- An embodiment provides a method of treating a condition selected from the group consisting of diabetes, obesity, and metabolic syndrome, comprising administering to a subject in need thereof, an effective amount of a compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt thereof.
- An embodiment provides a method of treating a condition selected from the group consisting of T2DM, obesity, and metabolic syndrome, comprising administering to a subject in need thereof, an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
- An embodiment provides a method for providing therapeutic weight loss comprising administering to a subject in need thereof, an effective amount of a compound of Formula I, or a
- An embodiment is a method of treating T2DM comprising administering to a subject in need thereof, and effective amount of a compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt thereof.
- An embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in therapy.
- An embodiment provides a compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt thereof, for use in therapy to treat a condition selected from the group consisting of diabetes, obesity, and metabolic syndrome.
- An embodiment provides a compound of Formula I, or a
- the condition is T2DM.
- the condition is obesity.
- the condition is type 1 diabetes (T1DM).
- the condition is diabetes in a patient receiving insulin therapy.
- the condition is metabolic syndrome.
- the compounds of Formula I, or a pharmaceutically acceptable salt thereof, may be useful in the treatment of a variety of symptoms or disorders.
- certain embodiments provide a method for treatment of T2DM in a patient comprising
- administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof is a method for treatment of obesity in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- the method is inducing non-therapeutic weight loss in a subject, comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method for treatment of metabolic syndrome in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- the method is treatment of diabetes in a patient receiving insulin treatment, comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- OXM oxyntomodulin agonist
- a compound of the present invention for use in simultaneous, separate, and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium-glucose cotransporter-2 (SGLT- 2) inhibitor, a growth differentiation factor 15 modulator (“GDF15”), a peptide tyrosine tyrosine analog (“PYY”), a modified insulin, an amylin receptor agonist, a dual amylin- calcitonin receptor agonist, a modified urocortin-2 (UCN-2) analog, a glucagon-like- peptide- 1 (GLP-1) receptor agonist, a glucagon receptor agonist, and a dual GLP-1- glucagon
- a compound of the present invention is provided in a fixed dose combination with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin-calcitonin receptor agonist, and OXM.
- a compound of the present invention is provided in a fixed dose combination with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin-calcitonin receptor agonist, and OXM.
- a compound of the present invention is provided in a fixed dose
- a thiazolidinedione a sulfonylurea
- a dipeptidyl peptidase 4 inhibitor a SGLT-2 inhibitor
- GDF15 a PYY analog
- a modified insulin an amylin receptor agonist, a dual amylin-calcitonin receptor agonist, a modified urocortin-2 (UCN-2) analog, a glucagon-like-peptide- 1 (GLP-1) receptor agonist, a glucagon receptor agonist, and a dual GLP-1 -glucagon receptor agonist including OXM and analogs thereof.
- a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin-calcitonin receptor agonist, and OXM in the treatment of a condition selected from the group consisting of T2DM and obesity.
- one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin-calcitonin receptor agonist, and OXM in the treatment of a condition selected from the group consisting of T2DM and obesity.
- a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a SGLT-2 inhibitor, GDF15, a PYY analog, a modified insulin, an amylin receptor agonist, a dual amylin-calcitonin receptor agonist, a modified urocortin-2 (UCN-2) analog, a glucagon-like-peptide- 1 (GLP-1) receptor agonist, a glucagon receptor agonist, and a dual GLP-1 glucagon receptor agonist including OXM and analogs of, in the treatment of a condition selected from the group consisting of T2DM and obesity.
- agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a
- a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, and a SGLT-2 inhibitor in the treatment of a condition selected from the group consisting of T2DM and obesity.
- an embodiment is a method for treating diabetes in a patient receiving insulin therapy, comprising administering an effective amount of a Compound of Formula I or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
- An embodiment is treatment to a patient administered insulin therapy for T1DM.
- An embodiment is treatment to patient administered insulin therapy for T2DM.
- An embodiment is once weekly dosing.
- An embodiment is subcutaneous treatment once weekly to a patient administered insulin therapy.
- the insulin therapy comprises basal insulin therapy.
- the insulin therapy comprises mealtime insulin therapy.
- the insulin therapy comprises ultra-rapid insulin therapy.
- Insulin therapy administered with acute infusions of a compound of Formula I, or a pharmaceutically acceptable salt thereof may enhance glucagon excursion in patients undergoing hypoglycemic clamp, thus enhancing the body's natural defense against hypoglycemia.
- insulin therapy means treatment of a patient with diabetes using an approved insulin treatment. Such insulin therapy is known to the skilled artisan and/or clinical health care professional. For example, insulin therapy may comprise treatment using basal insulin.
- basal insulin“insulin therapy” may be used in a dosing regimen with mealtime insulin and/or ultra-rapid insulin.
- mealtime insulin means insulin and/or modified insulin to be administered with meals, for example, but not limited to, insulin lispro.
- basal insulin means modified insulin with a longer duration of action, such as, for example, but not limited to, insulin glargine.
- Another embodiment provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition selected from the group consisting of T2DM, obesity, and metabolic syndrome.
- An embodiment provides the use of a compound of any one of embodiments 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition selected from the group consisting of diabetes, obesity, and metabolic syndrome.
- the medicament is for the treatment of T2DM
- the medicament is for the treatment of obesity.
- the medicament is for use in the treatment of diabetes in a patient receiving insulin therapy.
- Another embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one selected from the group consisting of a carrier, diluent, and excipient.
- a pharmaceutical composition for subcutaneous administration is provided.
- the term“treating” or“to treat” includes restraining, slowing, stopping, or reversing the progression or severity of a symptom, condition, or disorder.
- Certain compounds of the present invention are generally effective over a wide dosage range.
- dosages for once weekly parenteral dosing may fall within the range of 0.05 mg to about 60 mg per person per week.
- the compounds of Formul a I, or a pharmaceutically acceptable salt thereof, include novel amino acid sequences having affinity for the GIP receptor, with desired potency at the receptor.
- GIP is a 42 amino acid peptide (SEQ ID NO: 1), which, like GLP- 1, is known as an incretin, and it plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in the presence of glucose.
- GLP- 1 is a 36 amino acid peptide, the major biologically active fragment of which is produced as a 30-amino acid, C-terminal amidated peptide (GLP-1 7-36 ) (SEQ ID NO:2).
- Glucagon is a 29-amino acid peptide hormone (SEQ ID NO:3) secreted by a-cells of the islet of Langerhans in the pancreas and is involved in glucose homeostasis.
- the compounds of present invention provide desired potency at the GIP receptor with high degree of selectivity against the GLP-1R and the Glucagon receptor.
- compounds have desired GIP receptor activity with extended duration of action.
- amino acid means both naturally occurring amino acids and unnatural amino acids.
- “Orn” means L-omithine.
- “4Pal” means 3-(4- Pyridyl)-L- alanine.
- “aMeF(2F)” means alpha-methyl 2-fluoro-L- phenylalanine.
- “aMeY” and“aMeL” mean alpha-methyl-L-tyrosine and alpha-methyl-L- leucine, respectively.
- “e” and“D-Glu” mean D- glutamic acid.
- “D-Tyr”and“y” each mean D-tyrosine.
- D-Ala and“a” each mean D-alanine.
- “aMeF” means alpha-methyl-F and alpha-methyl-Phe.
- “Iva” means L-isovaline.
- the conjugation is an acylation. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.
- a fatty acid moiety is conjugated, via a linker, to a K at position 17. In an embodiment of the compounds of the present invention, a fatty acid moiety is conjugated, via a linker, to a K at position 26.
- q is selected from the group consisting of 16 and 18. In an embodiment, q is 16. In an embodiment, q is 18.
- the terms“activity,” “activate[s]”“activat[ing]” and the like refers to the capacity of a compound, or a pharmaceutically acceptable salt thereof, to bind to and induce a response at the receptor, as measured using assays known in the art, such as the in vitro assays described below.
- the affinity of compounds of Formula I, or a pharmaceutically acceptable salt thereof, for the GIP receptor may be measured using techniques known for measuring receptor binding levels in the art, including, for example, those described in the examples below, and is commonly expressed as a Ki value.
- the activity of the compounds of the present invention at the GIP receptor may also be measured using techniques known in the art, including for example the in vitro activity assays described below, and is commonly expressed as an EC 50 value, which is the concentration of compound causing half-maximal simulation in a dose response curve.
- a pharmaceutical composition of a compound of Formula I is suitable for administration by a parenteral route (e.g ., subcutaneous, intravenous, intraperitoneal, intramuscular, or transdermal).
- a parenteral route e.g ., subcutaneous, intravenous, intraperitoneal, intramuscular, or transdermal.
- Some pharmaceutical compositions and processes for preparing same are well known in the art. (See, e.g., Remington; The Science and Practice of Pharmacy (D.B. Troy, Editor, 21st Edition, Lippincott, Williams & Wilkins, 2006)).
- Compounds of the present invention may react with any of a number of inorganic and organic acids/bases to form pharmaceutically acceptable aci d/base addition salts.
- Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. (See, e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011)).
- Pharmaceutically acceptable salts of the present invention include, but are not limited to, sodium, trifluoroacetate, hydrochloride, ammonium, and acetate salts.
- a pharmaceutically acceptable salt is selected from the group consisting of sodium, hydrochloride, and acetate salts.
- the present invention also encompasses novel intermediates and processes useful for the synthesis of compounds of the present invention, or a pharmaceutically acceptable salt thereof.
- the intermediates and compounds of the present invention may be prepared by a variety of procedures known in the art. In particular, the Examples below describe a process using chemical synthesis. The specific synthetic steps for each of the routes described may be combined in different ways to prepare compounds of the present invention.
- the reagents and starting materials are readily available to one of ordinary skill in the art.
- the term“effective amount” refers to the amount or dose of a compound of the present invention, or a pharmaceutically acceptable salt thereof, which, upon single or multiple dose administration to the patient, provides the desired effect in the patient under diagnosis or treatment.
- An effective amount can be determined by a person of skill in the art using known techniques and by observing results obtained under analogous circumstances.
- a number of factors are considered, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- the term“subject in need thereof’ refers to a mammal, preferably a human, with a disease or condition requiring treatment or therapy, including for example those listed in the preceding paragraphs.
- “EDTA” means ethylenediaminetetraacetic acid.
- “DMSO” means dimethyl sulfoxide.
- “CPM” means counts per minute.
- “IBMX” means 3-isobutyl-1-methylxanthine.
- LC/'MS means liquid chromatography/mass spectrometry.
- “HTRF” means homogeneous time-resolved fluorescence.
- “DMF” refers to NN- dimethylformamide.
- “DCM” refers to dichloromethane.
- “TFA” refers to trifluoroacetic acid.
- “TEA salt” refers to trifluoroacetate salt.
- “RP-HPLC” means reversed-phase high performance liquid chromatography.
- SEQ ID NO:5 The structure of SEQ ID NO:5 is depicted below using the standard single letter amino acid codes with the exceptions of residues D-Ala2, K17, Aib20, and Ser39, where the structures of these amino acid residues have been expanded:
- Example 1 The peptide backbone of Example 1 is synthesized using
- the resin consists of aminomethyl polystyrene functionalized with a Rink Amide linker (polystyrene AM RAM, RAPP polymeric GmbH, H40023, 200-400 mesh) at a substitution of 0.8 rnmol/g.
- Standard side-chain protecting groups are used with the following exceptions: Fmoc-Lys(Mtt)-OH, where Mtt is 4-methyltrityl, is used for the lysine at position 17 and Boc-Tyr(t-Bu)-OH is used for the tyrosine at position 1.
- Fmoc groups are removed prior to each coupling step (2 x 10 minutes) using 20% piperidine in DMF.
- Ail standard amino acid couplings are performed using an equal molar ratio of Fmoc amino acid (0.3 M in DMF), diisopropylcarbodiimide (0.9 M in DCM) and Oxyma (0.9 M in DMF) at a 9-fold molar excess over the theoretical peptide loading. Couplings are allowed to proceed for 1.5 hours, with the following exceptions: coupling of valine, 3 hours; coupling of Ca-methylated amino acids, 6 hours; coupling to Ca- methylated amino acids, 6-10 hours. After completion of the synthesis of the peptide backbone, the resin is thoroughly washed with DCM to remove residual DMF.
- the Mtt protecting group on the lysine at position 17 is selectively removed from the peptide resin using three treatments of 30% hexafluoroisopropanol (Oakwood Chemicals) in DCM (3 x 20-minute treatment), and the resin is thoroughly washed with DCM and DMF.
- mono-OtBu-eicosanedioic acid (WuXi AppTec, Shanghai, China) is coupled for 1 hour using a 4-fold excess of the diacid, PyBOP, and diisopropylethylamine (1 : 1 : 1 mol/mol/mol) in 1 : 1 DCM/DMF.
- the peptide-resin is washed with DCM and then thoroughly dried over vacuum.
- the dry peptide-resin is treated with cleavage cocktail (10 mL TFA, 0.5 mL triisopropylsilane, 0.5 mL water, and 0.5 mL 1,2-ethanedithiol) for 2 hours at room temperature.
- the peptide resin solution is filtered into a 50-mL conical centrifuge tube and treated with 5-fold excess volume of cold diethyl ether (-20°C) to precipitate the crude peptide.
- the peptide/ether suspension is centrifuged at 3000 ref for 1.5 min. to form a solid pellet and the supernatant is decanted.
- the pellet is washed further two times with cold diethyl ether, centrifuging for 1 min. each time, then dried in vacuo.
- the crude peptide is solubilized in 20% acetic aci d/80% water and purified by RP-HPLC on a Symmetry Prep 7 mm C 18 preparative column (18 x 300 mm, Waters) with linear gradients of 100% acetonitrile and 0.1% TFA/water buffer system (25-45% acetonitrile in 65 min).
- the purity of peptide is assessed using analytical RP-HPLC and pooling criteria is >95%.
- the main pool purity of compound of example 1 is found to be 96.8%.
- Subsequent lyophilization of the final main product pool yielded the iyophiiized peptide TFA salt.
- the molecular weight is determined by LC/MS (Found:
- SEQ ID NO:6 The structure of SEQ ID NO:6 is depicted below using the standard single letter amino acid codes with the exceptions of residues D-Ala2, K17, Aib20, and Ser39, where the structures of these amino acid residues have been expanded:
- the compound according to SEQ ID NO:6 is prepared substantially as described by the procedures of Example 1, where instead the protected diacid is mono- OtBu-octadecanedioic acid (WuXi AppTec, Shanghai, China).
- SEQ ID NO:7 The structure of SEQ ID NO:7 is depicted below using the standard single letter amino acid codes with the exceptions of residues Aib2, aMeL13, K17, Aib20, 4-Pal25, and Ser39, where the structures of these amino acid residues have been expanded:
- the compound according to SEQ ID NO:7 is prepared substantially as described by the procedures of Example 1.
- SEQ ID NO:8 The structure of SEQ ID NO:8 is depicted below using the standard single letter amino acid codes with the exceptions of residues Aib2, aMeL13, Ornl6,
- the compound according to SEQ ID NO:8 is prepared substantially as described by the procedures of Example 1.
- SEQ ID NO:9 The structure of SEQ ID NO:9 is depicted below using the standard single letter amino acid codes with the exceptions of residues Aib2, aMeL13, Aib20, K26, and Ser39, where the structures of these amino acid residues have been expanded:
- the compound according to SEQ ID NO:9 is prepared substantially as described by the procedures of Example 1, where Fmoc-Lys(Mtt)-OH is used for the lysine at position 26 rather than at position 17.
- SEQ ID NO: 10 The structure of SEQ ID NO: 10 is depicted below using the standard single letter amino acid codes with the exceptions of residues Aib2, aMeL13, Orn16, Aib20, K26, and Ser39, where the structures of these amino acid residues have been expanded:
- the compound according to SEQ ID NO: 10 is prepared substantially as described by the procedures of Example 1, where Fmoc-Lys(Mtt)-OH is used for the lysine at position 26 rather than at position 17.
- SEQ ID NO: 11 The structure of SEQ ID NO: 11 is depicted below using the standard single letter amino acid codes with the exceptions of residues Aib2, aMeL13, Orn16, Aib20, D- Glu24, K26, and Ser39, where the structures of these amino acid residues have been expanded:
- the compound according to SEQ ID NO: 11 is prepared substantially as described by the procedures of Example 1, where Fmoc ⁇ Lys(Mtt)-OH is used for the lysine at position 26 rather than at position 17 and the protected diacid is mono-OtBu- octadecanedioic acid (W uXi AppTec, Shanghai, China).
- Example 8 SEQ ID NO: 12
- Example 122 SEQ ID NO: 1236
- Gcg or hGcg is a Reference Standard prepared at Eli Lilly and Company.
- GLP-1(7-36)-NH 2 (referred to as GLP-1 or hGLP-1) is obtained from CPC Scientific (Sunnyvale, CA, 97.2% purity, 100 mM aliquots in 100%
- GIP (1-42)-NH 2 (referred to as GIP) is prepared at Lilly Research
- [ 125 I]-radiolabeled Gcg, GLP-1, or GIP is prepared using [ 125 I]-lactoperoxidase and obtained from Perkin Elmer (Boston, MA).
- Stably transfected cell lines are prepared by subcloning receptor cDNA into a pcDNA3 expression plasmid and transfected into human embryonic kidney (HEK)
- hGcgR and hGLP-lR Chinese Hamster Ovary (CHO) (hGIPR) cells followed by selection with Geneticin (hGLP-lR and hGIPR) or hygromycin B (hGcgR).
- Method 1 Frozen cell pellets are lysed on ice in hypotonic buffer containing 50 mM Tris HC1, pH 7.5, and Roche CompleteTM Protease Inhibitors with EDTA.
- the cell suspension is disrupted using a glass Potter-Elvehjem homogenizer fitted with a Teflon ® pestle for 25 strokes.
- the homogenate is centrifuged at 4°C at 1100 x g for 10 minutes.
- the supernatant is collected and stored on ice while the pellets are resuspended in homogenization buffer and rehomogenized as described above.
- the homogenate is centrifuged at 1100 x g for 10 minutes.
- the second supernatant is combined with the first supernatant and centrifuged at 35000 x g for 1 hour at 4°C.
- the resulting membrane pellet is resuspended in homogenization buffer containing protease inhibitors at approximately 1 to 3 mg/mL, quick frozen in liquid nitrogen and stored as aliquots in a -80°C freezer until use.
- Method 2 Frozen cell pellets are lysed on ice in hypotonic buffer containing 50 mM Tris HCl, pH 7.5, 1 mM MgCl 2 , Roche CompleteTM EDTA-free Protease Inhibitors and 25 units/mL DNAse I (Invitrogen).
- the cell suspension is disrupted using a glass Potter- Elvehjem homogenizer fitted with a Teflon ® pestle for 20 to 25 strokes.
- the homogenate is centrifuged at 4°C at 1800 x g for 15 minutes. The supernatant is collected and stored on ice while the pellets are resuspended in homogenization buffer (without DNAse I) and rehomogenized as described above.
- the homogenate is centrifuged at 1800 x g for 15 minutes.
- the second supernatant is combined with the first supernatant and centrifuged an additional time at 1800 x g for 15 minutes.
- the overall supernatant is then centrifuged at 25000 x g for 30 minutes at 4°C.
- the resulting membrane pellet is resuspended in homogenization buffer (without DNAse I) containing protease inhibitors at approximately 1 to 3 mg/mL and stored as aliquots in a -80°C freezer until use.
- receptor/radioligand interactions are determined from homologous competition binding analysis instead of saturation binding due to high propanol content in the [ 125 I] stock material.
- the K d values determined for the receptor preparations were as follows: hGcgR (3.9 nM), hGLP-lR (1.2 nM) and hGIPR (0.14 nM).
- the human Gcg receptor binding assays are performed using a Scintillation Proximity Assay (SPA) format with wheat germ agglutinin (WGA) beads (Perkin Elmer).
- the binding buffer contains 25 mM 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES), pH 7.4, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 0.1% (w/v) bacitracin (Research Products), 0.003% (w/v) Polyoxyethylenesorbitan monolaurate (TWEEN ® -20), and Roche CompleteTM Protease Inhibitors without EDTA.
- HEPES 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid
- Peptides and Gcg are thawed and 3-fold serially diluted in 100% DMSO (10 point concentration response curves).
- 5 mL serially diluted compound or DMSO is transferred into Corning ® 3632 clear bottom assay plates containing 45 mL assay binding buffer or unlabeled Gcg control (non-specific binding or NSB, at 1 mM final).
- 50 mL human GcgR membranes 1.5 mg/well
- 50 mL of WGA SPA beads 80 to 150 mg/well
- Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta ® scintillation counter after 12 hours of incubation/settling time at room temperature.
- Final assay concentration ranges for peptides tested in response curves is typically 1150 nM to 0.058 nM and for the control Gcg from 1000 nM to 0.05 nM.
- the human GLP-1 receptor binding assay is performed using an SPA format with WGA beads.
- the binding buffer contains 25 mM HEPES, pH 7.4, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 0.1% (w/v) bacitracin, 0.003% (w/v) TWEEN ® -20, and Roche CompleteTM Protease Inhibitors without EDTA.
- Peptides and GLP-1 are thawed and 3- fold serially diluted in 100% DMSO (10 point concentration response curves).
- Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta ® scintillation counter after 5 to 12 hours of incubation/settling time at room temperature.
- Final assay concentration ranges for peptides tested in response curves are typically 1150 nM to 0.058 nM and for the control GLP-1, 250 nM to 0.013 nM.
- the human GIP receptor binding assay is performed using an SPA format with WGA beads.
- the binding buffer contains 25 mM HEPES, pH 7.4, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 0.1% (w/v) bacitracin, 0.003% (w/v) TWEEN ® -20, and Roche
- Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta ® scintillation counter after 2.5 to 12 hours of incubation/settling time at room temperature.
- Final assay concentration ranges for peptides tested in response curves is typically 1150 to 0.058 nM or 115 nM to 0.0058 nM and forthe control GIP, 250 nM to 0.013 nM.
- Raw CPM data for concentration curves of peptides, Gcg, GLP-1, or GIP are converted to percent inhibition by subtracting nonspecific binding (binding in the presence of excess unlabeled Gcg, GLP-1, or GIP, respectively) from the individual CPM values and dividing by the total binding signal, also corrected by subtracting nonspecific binding.
- Data are analyzed using four-parameter (curve maximum, curve minimum, IC 50 , Hill slope) nonlinear regression routines (Genedata Screener, version 12.0.4, Genedata AG, Basal, Switzerland).
- examples of the present invention are very potent binders of the human GIPR, and have lower affinity for the GLP-1R and GcgR.
- a set of cAMP assays are conducted in HEK293 cells expressing the human GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic peptide receptor (GIPR), or glucagon receptor (GcgR).
- GLP-1R human GLP-1 receptor
- GIPR glucose-dependent insulinotropic peptide receptor
- GcgR glucagon receptor
- Each receptor over-expressing cell line (20 ml) is treated with the test peptide in DMEM (Gibco Cat# 31053) supplemented with 0.1% Casein (Sigma Cat# C4765), 250 mM IBMX, IX GlutaMAXTM (Gibco Cat# 35050), and 20 mM HEPES (HyClone Cat# SH30237.01) in a 20 ml assay volume. After incubating for 60 minutes at room temperature, the resulting increase in intracellular cAMP is quantitatively determined using the CisBio cAMP Dynamic 2 HTRF Assay Kit
- EC50 is the concentration of compound causing half-maximal simulation in a dose response curve.
- a relative EC 50 value is derived by non-linear regression analysis using the percent maximal response vs. the concentration of peptide added, fitted to a four-parameter logistic equation.
- Example and comparator molecules are conducted to determine the intrinsic potency of Example and comparator molecules performed in the presence of casein (instead of serum albumin) as a nonspecific blocker, which does not interact with the fatty acid moieties of the analyzed molecules.
- Intracellular cAMP levels are determined by extrapolation using a standard curve. Dose response curves of compounds are plotted as the percentage of stimulation normalized to minimum (buffer only) and maximum (maximum concentration of each control ligand) values and analyzed using a four-parameter non-linear regression fit with a variable slope (Genedata Screener 13). EC 50 is the concentration of compound causing half-maximal simulation in a dose response curve. Each relative EC50 value for the geometric mean calculation is determined from a curve fitting.
- Concentration response curves of compounds are plotted as the percentage of stimulation normalized to minimum (buffer only) and maximum (maximum
- GM 10(arithmetic mean of log 10 transformed EC 50
- SEM geometric mean x (standard deviation of log 10 transformed EC 50 values / square root of the # of runs) x log e of 10.
- the log transform accounts for the EC 50 values falling on a multiplicative, rather than an arithmetic scale.
- test peptides are run plus the native ligands GIP, GLP-1, and glucagon, buffer only as baseline (minimum) and the highest concentration of the respective GIP, GLP-1, and glucagon standard is used as maximum for calculations.
- the peptide is tested in 8 runs of the hGIPR cAMP assay.
- hGIP amide, hGLP-1 amide, and glucagon EC50 in Table 2 are illustrative of geometric mean values from a series of 18 assay values, and values will vary each day compared to the zero buffer. Accordingly, each Example will use the geometric mean of those values to normalize the Example assay runs. Table 2. Functional activation of hGcgR, hGIPR, and hGLP-1R in the presence of 0.1% Casein.
- Example compounds of the present invention are very potent stimulating cAMP from human GIPR in the presence of 0.1% casein.
- the pharmacokinetics of select Examples are evaluated following a single subcutaneous administration of 50 nmol/kg to male cynomolgus monkeys. Blood samples are collected over 504 hours and resulting individual plasma concentrations are used to calculate pharmacokinetic parameters. Peptide plasma (K 3 EDTA) concentrations are determined using a qualified LC/MS method that measured the intact mass of the compound. Each peptide and an analog as an internal standard are extracted from 100% cynomolgus monkey plasma using a protein precipitation method. Instruments are combined for LC/MS detection. Mean pharmacokinetic parameters are shown in Table 3.
- T 1/2 half-life
- T max time to maximal concentration
- C max /dose maximal plasma concentration divided by dose
- AUC Inf /Dose AUC Inf divided by dose
- the pharmacokinetics of select Examples are evaluated following a single subcutaneous (SC) administration of 100 nmol/kg to male Sprague Dawley rats. Blood samples are collected over 168 hours following SC administration. Pharmacokinetic parameters are calculated using individual plasma concentrations. A qualified LC/MS method that measures the intact mass of the Example is used to determine plasma (K 3 EDTA) concentrations. Each peptide and an analog as an internal standard are extracted from 100% rat plasma using a protein precipitation method. Instruments are combined for LC/MS detection. Mean pharmacokinetic parameters for the Examples are shown in Table 4
- T 1/2 half-life
- T max time to maximal concentration
- C max /Dose maximal plasma concentration divided by dose
- AUC Inf /Dose AUC Inf divided by dose
- CL/F clearance/bioavailability.
- Rats maintained on a 12: 12 h light-dark cycle (lights on at 6:00 A.M.) at 21°C and receive food and deionized water ad libitum. Rats are randomized by body weight and dosed 1.5 mL/kg subcutaneously (s.c.) at doses of 0.3, 1.0, 3, 10, 30, and 100 nmol/kg 16 hours prior to glucose administration then fasted. Animals are weighed and anesthetized with sodium pentobarbital dosed intraperitoneally (i.p.) (65 mg/kg, 30 mg/mL).
- i.p. sodium pentobarbital dosed intraperitoneally
- a blood sample is collected into EDTA tubes after which glucose is administered intravenously (i.v.) (0.5 mg/kg, 5 mL/kg).
- Blood samples are collected for glucose and insulin levels at 2, 4, 6, 10, 20 and 30 min post- intravenous administration of glucose.
- Plasma glucose levels are determined using a clinical chemistry analyzer.
- Plasma insulin is determined using an
- CD4+ T Cell Assay The CD4+ T cell assay is used to compare the compounds of Examples 1, 2, 3, 5, and 6 for a potential to induce an immune response in vivo according to methods known in the art (see, e.g., Jones et al. (2004) J. Interferon Cytokine Res. 24:560-572; and Jones et al. (2005) . Thromb. Haemost. 3:991-1000), where an assessment of clinically tested monoclonal antibodies and peptides shows some degree of correlation between T cell proliferation observed in vitro and immunogenicity in the clinic. Protein therapeutics that induce less than 30% positive response in the CD4+ T cell proliferation assay are associated with a low risk of immunogenicity.
- T cell- depleted peripheral blood mononuclear cells are prepared and labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) from a cohort of 10 healthy donors with diverse human leukocyte antigen (HLA) class II haplotypes. Each donor is tested in triplicate with 2.0 mL media control, keyhole limpet hemocyanin (KLH; 0.33 mM), and the compounds of Examples 1, 2, 3, 5, and 6 (0.33 mM). Cultures are incubated for 7 days at 37°C with 5% CO 2 .
- CSE carboxyfluorescein diacetate succinimidyl ester
- samples are analyzed by flow cytometry using a BD LSR II Fortessa (Becton Dickinson; Franklin Lakes, NJ), equipped with a high throughput sampler (HTS). Data is analyzed using FlowJo® Software (FlowJo, LLC/TreeStar; Ashland, OR).
- Table 7 CD4+ T Cell Responses for Example compounds and Positive Control (KLH).
- CDI Cell Division Index
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227002903A KR20220028007A (en) | 2019-08-01 | 2020-07-29 | GIPR-agonist compounds |
MX2022001137A MX2022001137A (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds. |
CA3145608A CA3145608A1 (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds |
AU2020322784A AU2020322784A1 (en) | 2019-08-01 | 2020-07-29 | GIPR-agonist compounds |
CN202080056086.3A CN114206915A (en) | 2019-08-01 | 2020-07-29 | GIPR-agonist compounds |
JP2022506052A JP7230272B2 (en) | 2019-08-01 | 2020-07-29 | GIPR agonist compounds |
PE2022000145A PE20220938A1 (en) | 2019-08-01 | 2020-07-29 | GIPR AGONIST COMPOUNDS |
BR112022000027A BR112022000027A2 (en) | 2019-08-01 | 2020-07-29 | gipr agonist compounds |
CR20220020A CR20220020A (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds |
JOP/2022/0024A JOP20220024A1 (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds |
EP20758004.4A EP4007593A1 (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds |
IL289463A IL289463A (en) | 2019-08-01 | 2021-12-28 | Gipr-agonist compounds |
CONC2022/0000759A CO2022000759A2 (en) | 2019-08-01 | 2022-01-27 | gipr agonist compounds |
DO2022000025A DOP2022000025A (en) | 2019-08-01 | 2022-01-31 | GIPR AGONIST COMPOUNDS |
JP2023021452A JP2023062068A (en) | 2019-08-01 | 2023-02-15 | Gipr-agonist compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962881685P | 2019-08-01 | 2019-08-01 | |
US62/881,685 | 2019-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021021877A1 true WO2021021877A1 (en) | 2021-02-04 |
Family
ID=72145469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/043988 WO2021021877A1 (en) | 2019-08-01 | 2020-07-29 | Gipr-agonist compounds |
Country Status (20)
Country | Link |
---|---|
US (2) | US11254721B2 (en) |
EP (1) | EP4007593A1 (en) |
JP (2) | JP7230272B2 (en) |
KR (1) | KR20220028007A (en) |
CN (1) | CN114206915A (en) |
AR (1) | AR119471A1 (en) |
AU (1) | AU2020322784A1 (en) |
BR (1) | BR112022000027A2 (en) |
CA (1) | CA3145608A1 (en) |
CL (1) | CL2022000140A1 (en) |
CO (1) | CO2022000759A2 (en) |
CR (1) | CR20220020A (en) |
DO (1) | DOP2022000025A (en) |
EC (1) | ECSP22008098A (en) |
IL (1) | IL289463A (en) |
JO (1) | JOP20220024A1 (en) |
MX (1) | MX2022001137A (en) |
PE (1) | PE20220938A1 (en) |
TW (1) | TWI764209B (en) |
WO (1) | WO2021021877A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI764209B (en) * | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr-agonist compounds |
TW202317173A (en) * | 2020-12-18 | 2023-05-01 | 美商美國禮來大藥廠 | Dual amylin and calcitonin receptor agonists and uses thereof |
WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
CN116410298B (en) * | 2023-06-06 | 2023-08-11 | 诺博泰科(成都)生物科技有限公司 | Tri-agonism polypeptide compound and salt, pharmaceutical composition, medicament and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
WO2016066744A2 (en) * | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
WO2016111971A1 (en) | 2015-01-09 | 2016-07-14 | Eli Lilly And Company | Gip and glp-1 co-agonist compounds |
US20180155407A1 (en) * | 2016-12-02 | 2018-06-07 | Sanofi | Compounds as peptidic glp1/glucagon/gip receptor agonists |
WO2018181864A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Gip receptor activating peptide |
WO2019125929A1 (en) * | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Incretin analogs and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220135638A1 (en) | 2018-09-24 | 2022-05-05 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
US20220016215A1 (en) | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
TWI764209B (en) * | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr-agonist compounds |
-
2020
- 2020-07-23 TW TW109124879A patent/TWI764209B/en active
- 2020-07-23 AR ARP200102070A patent/AR119471A1/en unknown
- 2020-07-29 CN CN202080056086.3A patent/CN114206915A/en active Pending
- 2020-07-29 BR BR112022000027A patent/BR112022000027A2/en unknown
- 2020-07-29 EP EP20758004.4A patent/EP4007593A1/en active Pending
- 2020-07-29 WO PCT/US2020/043988 patent/WO2021021877A1/en active Application Filing
- 2020-07-29 CR CR20220020A patent/CR20220020A/en unknown
- 2020-07-29 US US16/941,990 patent/US11254721B2/en active Active
- 2020-07-29 CA CA3145608A patent/CA3145608A1/en active Pending
- 2020-07-29 JP JP2022506052A patent/JP7230272B2/en active Active
- 2020-07-29 MX MX2022001137A patent/MX2022001137A/en unknown
- 2020-07-29 KR KR1020227002903A patent/KR20220028007A/en active Search and Examination
- 2020-07-29 PE PE2022000145A patent/PE20220938A1/en unknown
- 2020-07-29 JO JOP/2022/0024A patent/JOP20220024A1/en unknown
- 2020-07-29 AU AU2020322784A patent/AU2020322784A1/en active Pending
-
2021
- 2021-12-28 IL IL289463A patent/IL289463A/en unknown
-
2022
- 2022-01-11 US US17/573,317 patent/US11897926B2/en active Active
- 2022-01-20 CL CL2022000140A patent/CL2022000140A1/en unknown
- 2022-01-27 CO CONC2022/0000759A patent/CO2022000759A2/en unknown
- 2022-01-31 DO DO2022000025A patent/DOP2022000025A/en unknown
- 2022-02-01 EC ECSENADI20228098A patent/ECSP22008098A/en unknown
-
2023
- 2023-02-15 JP JP2023021452A patent/JP2023062068A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
WO2016066744A2 (en) * | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
WO2016111971A1 (en) | 2015-01-09 | 2016-07-14 | Eli Lilly And Company | Gip and glp-1 co-agonist compounds |
US20180155407A1 (en) * | 2016-12-02 | 2018-06-07 | Sanofi | Compounds as peptidic glp1/glucagon/gip receptor agonists |
WO2018181864A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Gip receptor activating peptide |
WO2019125929A1 (en) * | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Incretin analogs and uses thereof |
Non-Patent Citations (5)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT, WILLIAMS & WILKINS |
JONES ET AL., J THROMB. HAEMOST., vol. 3, 2005, pages 991 - 1000 |
JONES ET AL., J. INTERFERON CYTOKINE RES., vol. 24, 2004, pages 560 - 572 |
LORENZ MARTIN ET AL: "Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 23, no. 14, 16 May 2013 (2013-05-16), pages 4011 - 4018, XP028573319, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.05.022 * |
P. STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2011, WILEY-VCH |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
WO2024003400A1 (en) | 2022-07-01 | 2024-01-04 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Also Published As
Publication number | Publication date |
---|---|
JP2023062068A (en) | 2023-05-02 |
US11254721B2 (en) | 2022-02-22 |
DOP2022000025A (en) | 2022-03-15 |
CR20220020A (en) | 2022-02-14 |
BR112022000027A2 (en) | 2022-05-24 |
CO2022000759A2 (en) | 2022-02-07 |
US20220127315A1 (en) | 2022-04-28 |
ECSP22008098A (en) | 2022-03-31 |
IL289463A (en) | 2022-02-01 |
CL2022000140A1 (en) | 2022-09-30 |
TW202126680A (en) | 2021-07-16 |
JP7230272B2 (en) | 2023-02-28 |
JOP20220024A1 (en) | 2023-01-30 |
MX2022001137A (en) | 2022-02-16 |
KR20220028007A (en) | 2022-03-08 |
JP2022544061A (en) | 2022-10-17 |
EP4007593A1 (en) | 2022-06-08 |
CA3145608A1 (en) | 2021-02-04 |
CN114206915A (en) | 2022-03-18 |
TWI764209B (en) | 2022-05-11 |
PE20220938A1 (en) | 2022-05-31 |
US20210032299A1 (en) | 2021-02-04 |
US11897926B2 (en) | 2024-02-13 |
AR119471A1 (en) | 2021-12-22 |
AU2020322784A1 (en) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11897926B2 (en) | GIPR-agonist compounds | |
KR102351313B1 (en) | GIP/GLP1 co-agonist compounds | |
AU2021211451B2 (en) | GIP/GLP1 co-agonist compounds | |
TWI790850B (en) | Dual amylin and calcitonin receptor agonists and uses thereof | |
JP7212171B2 (en) | Glucagon analogue agonists and methods of use thereof | |
WO2024059674A1 (en) | Gip and glp-1 dual agonist compounds | |
KR20240051304A (en) | Gip/glp1 co-agonist compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20758004 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022000027 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 3145608 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20227002903 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022506052 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020322784 Country of ref document: AU Date of ref document: 20200729 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022000027 Country of ref document: BR Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE US 62/881,685 DE 01/08/2019 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO E A DECLARACAO NAO CONTEM OS DADOS DA PRIORIDADE. |
|
ENP | Entry into the national phase |
Ref document number: 2020758004 Country of ref document: EP Effective date: 20220301 |
|
ENP | Entry into the national phase |
Ref document number: 112022000027 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220103 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522431576 Country of ref document: SA |